A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market
Drug development for hepatitis C virus (HCV) antivirals has amplified with rising incidence rates and the intense need for curative therapy in the absence of a preventative vaccine. Change is underway as the market moves away from protease inhibitors and interferon regimens towards highly effective, easily-tolerated, interferon-free oral therapies.
Gilead’s mega blockbuster Sovaldi is the first of these novel therapies to launch into the market and is projected to hit close to $10 billion during its first year. Several strong competitors, however, are maneuvering aggressively to narrow the market gap by introducing a HCV antiviral that can outdo Gilead’s drug.
New analysis from Frost & Sullivan’s "A Product and Pipeline Analysis of the Global Hepatitis C Virus (HCV) Antiviral Market" expects robust demand for HCV antivirals as around 160 million people across the globe are chronically infected with HCV, and at least 350,000 die annually from HC-infected liver diseases such as liver cancer and conditions requiring transplantation. The United States alone accounts for nearly five million of the total HCV-affected population, with the majority being baby boomers entering the 65-plus age bracket.
“Evidently, chronic infection with HCV remains a serious public health threat,” said Frost & Sullivan Healthcare Principal Analyst Randy Budros. “Until an efficacious preventative vaccine emerges, the patient strength will remain sizable due to the likelihood of high-risk behaviors from a substantial portion of the population and the emergence of resistant viral strains.”
While Gilead’s Sovaldi holds promise in fighting the HCV, its astronomical price — $84,000 for a 12-week course of treatment — has unleashed a firestorm of criticism from government agencies, patient advocacy groups, and payers. Indeed, the prohibitive price has triggered a Congressional request for Gilead to justify its pricing, which is projected to increase Medicare Part D spending by as much as $6.5 billion in 2015 alone.
“Gilead and other future market entrants have to create a compelling pricing rationale by driving home the potential cost savings from a high-performance, all-oral regime, zeroing in on the downstream cost saving such as the reduction of liver transplants,” noted Budros. “Equally crucial is the need to make HCV antivirals more affordable and accessible to patients.”
With recent clinical data showing close to 100% cure rates for Sovaldi, future contenders will be hard pressed to succeed in the marketplace. Competitors must aim to satisfy the until now unmet need for a once-daily, ribavirin-free, all-oral, pan-genotypic regimen that has a short treatment duration.
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance